SCHEMBL23328571

SCHEMBL23328571

COc1cc(OC)c(Cl)c(B2OC(C)(C)C(C)(C)O2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 3/20 0.39
ALDH1A1 P00352 5/20 0.36
KDM4E B2RXH2 2/20 0.36
GLA P06280 2/20 0.36
HPGD P15428 2/20 0.36
HSD17B10 Q99714 2/20 0.36
MEN1 O00255 1/20 0.36
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36
UCHL1 P09936 1/20 0.34
SNCA P37840 1/20 0.33
CYP3A4 P08684 3/20 0.33
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA7 P43166 1/20 0.32
CA9 Q16790 1/20 0.32
CA14 Q9ULX7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL263916 0.87 EGFR (0.40) EGFRKDM4EHPGDUCHL1CSF1R
SCHEMBL12642051 0.85 UCHL1 (0.35) EGFRALDH1A1KDM4EGLAHPGD
SCHEMBL264265 0.85 UCHL1 (0.35) EGFRALDH1A1UCHL1SNCACA1
SCHEMBL29517727 0.85 UCHL1 (0.35) EGFRALDH1A1UCHL1SNCACA1
SCHEMBL5899744 0.78 CA1 (0.38) ALDH1A1KDM4EGLAHPGDHSD17B10
SCHEMBL1426162 0.77 ALDH1A1 (0.33) EGFRALDH1A1KDM4EGLAHPGD
SCHEMBL2027567 0.77 ERN1 (0.50) ALDH1A1HPGDLMNAMAPTUCHL1
SCHEMBL5899720 0.77 CA2 (0.47) EGFRALDH1A1HPGDMEN1MAPT
SCHEMBL16760910 0.77 CA1 (0.47) EGFRALDH1A1HSD17B10MEN1MAPT
SCHEMBL30583102 0.77 CA1 (0.47) EGFRALDH1A1HSD17B10MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11365196-B2 FGFR inhibitor and application thereof BETTA PHARMACEUTICALS CO., LTD. (CN) 2022-06-21 US disclosed
US-20210130353-A1 FGFR INHIBITOR AND APPLICATION THEREOF BETTA PHARMACEUTICALS CO., LTD. (CN) 2021-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11365196-B2 FGFR inhibitor and application thereof FGFR1, FGFR4, FGFR2 EGFR 43/4885ALDH1A1 748/4885KDM4E 1695/4885
US-20210130353-A1 FGFR INHIBITOR AND APPLICATION THEREOF FGFR1, FGFR4, FGFR2 EGFR 44/4885ALDH1A1 642/4885KDM4E 1724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.